[{"orgOrder":0,"company":"Biomay","sponsor":"BioNTech","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2021","type":"Partnership","leadProduct":"Tozinameran","moa":"SARS-CoV-2 spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Biomay","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Biomay \/ BioNTech","highestDevelopmentStatusID":"12","companyTruncated":"Biomay \/ BioNTech"}]

Find Clinical Drug Pipeline Developments & Deals by Biomay

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : Biomay is one of the manufacturers supplying BioNTech with the DNA template for the in-vitro transcription of their mRNA active ingredient. The manufacturing agreement was initiated during the clinical development phase of the Comirnaty vaccine in Q1/202...

                          Brand Name : Comirnaty

                          Molecule Type : Vaccine

                          Upfront Cash : Undisclosed

                          May 17, 2021

                          Lead Product(s) : Tozinameran

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Approved

                          Sponsor : BioNTech

                          Deal Size : Undisclosed

                          Deal Type : Partnership

                          blank